Patents by Inventor Stephen M. Boue
Stephen M. Boue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9669004Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: GrantFiled: January 15, 2015Date of Patent: June 6, 2017Assignees: The Administrators of the Tulane Educational Fund, United States Department of Agriculture, Xavier University of LouisianaInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Publication number: 20170065554Abstract: The present disclosure encompasses, among other things, compositions and methods of enhancing glyceollin content of soybean tissue as well as methods of large-scale production of soybean tissues comprising elevated glyceollin content. The present disclosure further encompasses administration of food products comprising glyceollins in the treatment or prevention (i.e., delay of onset) of overweight, obesity, prediabetes, diabetes, IBD, and gastrointestinal dysbiosis.Type: ApplicationFiled: February 20, 2015Publication date: March 9, 2017Inventors: Mark L. HEIMAN, Stephen M. BOUE
-
Patent number: 9227898Abstract: It has been discovered that irradiating the cut side of sugarcane billets, preferably 2-50 mm, with UVB or UVC light or combinations thereof initiates stilbene production, particularly resveratrol and piceatannol. In an embodiment the cut sides of sugarcane billets of a predetermined thickness are irradiated with Ultraviolet-C or Ultraviolet-B light or combinations thereof at an intensity and for a duration of time sufficient to produce a significant increase in a level of one or more stilbenes in the irradiated billets compared to a level of stilbenes in billets that are not irradiated; and the irradiated sugarcane billets are maintained for at least about three days up to about 20 days, to optimize stilbene levels.Type: GrantFiled: January 28, 2013Date of Patent: January 5, 2016Assignee: The Administrators of the Tulane Edcational FundInventors: Stephen M. Boue, Matthew E. Burow, Deepak Bhatnagar
-
Publication number: 20150148409Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: ApplicationFiled: January 15, 2015Publication date: May 28, 2015Inventors: Guangdi WANG, Matthew E. BUROW, Stephen M. BOUE, Thomas E. WIESE, Quan JIANG
-
Patent number: 8987198Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.Type: GrantFiled: December 22, 2010Date of Patent: March 24, 2015Assignees: The Administrators of the Tulane Educational Fund, The United States Department of Agriculture, Wake Forest University Health Sciences, Nume Health, LLCInventors: Matthew E. Burow, Stephen M. Boue, Thomas T. Y. Wang, Deepak Bhatnagar, Charles E. Wood, Mark L. Helman
-
Patent number: 8962679Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: GrantFiled: July 8, 2011Date of Patent: February 24, 2015Assignees: The Administrators of the Tulane Educational Fund, Xavier University of LouisianaInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Publication number: 20150005533Abstract: It has been discovered that irradiating the cut side of sugarcane billets, preferably 2-50 mm, with UVB or UVC light or combinations thereof initiates stilbene production, particularly resveratrol and piceatannol. In an embodiment the cut sides of sugarcane billets of a predetermined thickness are irradiated with Ultraviolet-C or Ultraviolet-B light or combinations thereof at an intensity and for a duration of time sufficient to produce a significant increase in a level of one or more stilbenes in the irradiated billets compared to a level of stilbenes in billets that are not irradiated; and the the irradiated sugarcane billets are maintained for at least about three days up to about 20 days, to optimize stilbene levels.Type: ApplicationFiled: January 28, 2013Publication date: January 1, 2015Applicant: THE ADMINISTRATORS OF THE TULANE EDCATIONAL FUNDInventors: Stephen M. Boue, Matthew E. Burow, Deepak Bhatnagar
-
Patent number: 8563599Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.Type: GrantFiled: March 3, 2009Date of Patent: October 22, 2013Assignees: The United States of America, represented by the Secretary of Agriculture, Xavier University of Louisiana, University of ToledoInventors: Paul W. Erhardt, Rahul Khupse, Jefferey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McLachlan
-
Patent number: 8497249Abstract: CAY-1 is a fungicidal saponin from the cayenne pepper (Capsicum frutescens) fruit. The saponins 1081 and 919, closely elute with, and are close structural relatives of, CAY-1. Saponin 1081 is poorly antifungal while 919 has no antifungal properties. Nongerminated and germinating conidia of Aspergilus flavus, A. fumigatus, A. niger, Fusarium oxysporum, F. solani, and F. verticilioides were tested against pure CAY-1 and CAY-1:1081:919 at ratios of 8:1:1, 6:2:2 and 4:3:3 and efficacy was determined after various incubation times. Pure CAY-1 and all saponin mixtures were significantly (p<0.001) lethal to the germinating conidia of A. flavus, A. niger, and F. solani. All saponin mixtures were equal or superior to pure CAY-1 in antifungal properties. Mixtures of the naturally occurring inactive or poorly fungicidal saponins with reduced levels of CAY-1 display superior fungicidal properties when compared to pure CAY-1 at the same dose levels.Type: GrantFiled: October 2, 2009Date of Patent: July 30, 2013Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Anthony J. De Lucca, Stephen M. Boue
-
Publication number: 20130184475Abstract: Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.Type: ApplicationFiled: July 8, 2011Publication date: July 18, 2013Applicants: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, XAVIER UNIVERSITY OF LOUISIANNA, UNITED STATES DEPARTMENT OF AGRICULTUREInventors: Guangdi Wang, Matthew E. Burow, Stephen M. Boue, Thomas E. Wiese, Quan Jiang
-
Publication number: 20130041022Abstract: The present disclosure demonstrates the molecular effects of glyceollins on human prostate cancer cell LNCaP to further elucidate its potential effects on prostate cancer prevention. The glyceollins inhibited LNCaP cell growth similar to that of the soy isoflavone genistein. The growth inhibitory effects of the glyceollins appeared to be due to an inhibition on G1/S progression and correlated with an up-regulation of cyclin-dependent kinase inhibitor A1 and B1 mRNA and protein levels. By contrast, genistein only up-regulates cyclin-dependent kinase inhibitor A1. In addition, glyceollin treatments led to down-regulated mRNA levels for androgen responsive genes. In contrast to genistein, this effect of glyceollins on androgen responsive genes appeared to be mediated through modulation of an estrogen- but not androgen-mediated pathway.Type: ApplicationFiled: December 22, 2009Publication date: February 14, 2013Applicants: UNITED STATES DEPARTMENT OF AGRICULTURE, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Thomas E. Cleveland, Stephen M. Boue, Matthew E. Burow, Thomas T.Y. Wang
-
Patent number: 8323706Abstract: The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function.Type: GrantFiled: April 11, 2008Date of Patent: December 4, 2012Assignees: The United States of America, as represented by the Secretary of Agriculture, Tulane Educational FundInventors: Thomas E. Cleveland, Stephen M. Boue, Matthew E. Burow, John A. McLachlan
-
Publication number: 20110237505Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.Type: ApplicationFiled: December 22, 2010Publication date: September 29, 2011Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Matthew E. BUROW, Stephen M. BOUE, Thomas T.Y. WANG, Deepak BHATNAGAR, Charles E. WOOD, Mark A. HEIMAN
-
Publication number: 20110144195Abstract: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents.Type: ApplicationFiled: March 3, 2009Publication date: June 16, 2011Inventors: Paul W. Erhardt, Rahul Khupse, Jeffrerey G. Sarver, Thomas E. Cleveland, Stephen M. Boue, Thomas E. Wiese, Matthew E. Burow, John A. McClachlan
-
Publication number: 20080200537Abstract: The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function.Type: ApplicationFiled: April 11, 2008Publication date: August 21, 2008Inventors: Thomas E. Cleveland, Stephen M. Boue, Matthew E. Burow, John A. McLachlan